Review
Biochemistry & Molecular Biology
Patricia Richter, Anca Cardoneanu, Ciprian Rezus, Alexandra Maria Burlui, Elena Rezus
Summary: Cardiovascular diseases are a leading cause of high mortality in SLE patients, and traditional risk factors are insufficient in predicting their risk. Inflammation has been found to play a crucial role in the development of atherosclerosis in SLE, highlighting the need for new biomarkers to assess subclinical CVD risk.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Rheumatology
Jorge Luis Gamboa, Daniel Carranza-Leon, Rachelle Crescenzi, Michael Pridmore, Dungeng Peng, Adriana Marton, Annette Oeser, Cecilia P. Chung, Jens Titze, Charles Michael Stein, Michelle Ormseth
Summary: This study found that patients with SLE have increased intermuscular adipose tissue (IMAT) accumulation, which is associated with greater fatigue and reduced physical activity. Interventions targeting muscle quality may be effective in alleviating fatigue in SLE patients.
LUPUS SCIENCE & MEDICINE
(2022)
Review
Medicine, General & Internal
Johan Frostegard
Summary: The prognosis in systemic lupus erythematosus (SLE) has improved, but cardiovascular disease (CVD) still remains a significant clinical problem. Atherosclerosis and antiphospholipid antibody syndrome are the main underlying causes of CVD in SLE. Inflammation and low levels of anti-phosphorylcholine also contribute to the increased risk of CVD in SLE. Close monitoring and treatment of both traditional and non-traditional risk factors are important.
JOURNAL OF INTERNAL MEDICINE
(2023)
Review
Rheumatology
Resit Yildirim, Tatiana Oliveira, David Alan Isenberg
Summary: In recent years, there have been efforts to improve the prognosis and outcome in patients with autoimmune inflammatory rheumatic diseases by using treat-to-target strategy and early intervention strategies with immunosuppressive agents. However, infectious complications due to medication side effects remain a major concern. Vaccination programmes and vaccine immunity play a crucial role in patients with SLE in terms of morbidity and mortality. Although research on vaccines' efficacy and immune response in immunosuppressed patients has increased, there is still a lack of data investigating these parameters for those receiving biological agents, leading to a lack of consensus on a vaccination policy for patients with SLE.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Review
Cell Biology
Allison B. Reiss, Benna Jacob, Saba Ahmed, Steven E. Carsons, Joshua DeLeon
Summary: Despite advancements in treating lupus, there is still a lack of innovative therapeutics specifically targeting the progression of atherosclerosis within the SLE population. Development of promising modalities for diagnosis of subclinical atherosclerosis and detection of high CVD risk patients has been achieved, but research addressing prevention and treatment of CVD in SLE needs to be prioritized due to its significant impact on morbidity and mortality.
Review
Immunology
Qian Chen, Jie Wang, Mengmeng Xiang, Yilun Wang, Zhixiong Zhang, Jun Liang, Jinhua Xu
Summary: This review summarizes the potential links between ferroptosis and systemic lupus erythematosus (SLE), elucidates the role of ferroptosis in SLE pathogenesis, and proposes a new therapeutic strategy for SLE.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Rheumatology
Xiaochan Chen, Xiaowei Shi, Han Xue, Honghua Lv, Lishi Yu, Xiudi Wu, Qiaohong Wang, Huaxiang Wu, Fei Han, Jing Xue
Summary: This multicentre prospective cohort study demonstrates that long-term RTX maintenance therapy has high efficacy and acceptable safety in relapsing or refractory SLE patients who had a clinical response to RTX induction therapy.
Article
Rheumatology
George C. Drosos, George Konstantonis, Petros P. Sfikakis, Maria G. Tektonidou
Summary: This study examined the eligibility for lipid-lowering therapy (LLT) in SLE patients according to SCORE, with the addition of vascular ultrasound and disease-related features. The results showed that disease-related and ultrasound features can help improve LLT decision making in SLE.
Article
Rheumatology
Sarfaraz Hasni, Yenealem Temesgen-Oyelakin, Michael Davis, Jun Chu, Elaine Poncio, Mohammad Naqi, Sarthak Gupta, Xinghao Wang, Christopher Oliveira, Dillon Claybaugh, Amit Dey, Shajia Lu, Philip Carlucci, Monica Purmalek, Zerai G. Manna, Yinghui Shi, Isabel Ochoa-Navas, Jinguo Chen, Amrita Mukherjee, Kyu Lee Han, Foo Cheung, Galina Koroleva, Yasmine Belkaid, John S. Tsang, Richard Apps, Donald E. Thomas, Theo Heller, Massimo Gadina, Martin P. Playford, Xiaobai Li, Nehal N. Mehta, Mariana J. Kaplan
Summary: The study aimed to investigate the effects of the peroxisome proliferator activated receptor-gamma agonist pioglitazone (PGZ) on vascular function and cardiometabolic parameters in SLE patients. The results showed that PGZ significantly improved vascular stiffness and metabolic parameters in SLE patients.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Review
Peripheral Vascular Disease
Rachel Tobin, Nidhi Patel, Kardie Tobb, Brittany Weber, Puja K. Mehta, Ijeoma Isiadinso
Summary: SLE patients have an increased risk of cardiovascular disease (CVD) despite most patients being young females not traditionally considered at high risk. The increased risk is multifactorial, involving proatherogenic lipid profiles, immune dysregulation and inflammation, lupus treatment side effects, and microvascular dysfunction. Conventional CV risk models often fail to identify SLE patients at high risk for atherosclerosis. Non-invasive imaging is useful for identifying subclinical CVD and evaluating symptomatic patients. Prompt detection and treatment of atherosclerotic CVD in SLE patients is crucial.
CURRENT ATHEROSCLEROSIS REPORTS
(2023)
Article
Cardiac & Cardiovascular Systems
Brittany N. Weber, Emma Stevens, Leanne Barrett, Camden Bay, Corine Sinnette, Jenifer M. Brown, Sanjay Divakaran, Courtney Bibbo, Jon Hainer, Sharmila Dorbala, Ron Blankstein, Katherine Liao, Elena Massarotti, Karen Costenbader, Marcelo F. Di Carli
Summary: This study found that patients with systemic lupus erythematosus (SLE) without obstructive coronary artery disease have a high prevalence of coronary vasomotor abnormalities. This phenomenon is not solely explained by common cardiovascular factors or atherosclerotic burden.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2021)
Article
Rheumatology
Gabriela Pocovi-Gerardino, Maria Correa-Rodriguez, Jose-Luis Callejas-Rubio, Raquel Rios-Fernandez, Maria Martin-Amada, Maria-Gracia Cruz-Caparros, Blanca Rueda-Medina, Norberto Ortego-Centeno
Summary: The study showed that greater adherence to the Mediterranean diet is associated with better anthropometric profiles, fewer cardiovascular disease risk factors, and lower disease activity and damage accrual scores in SLE patients. A higher Mediterranean diet score was linked to reduced odds of active SLE or the presence of damage. The results suggest a beneficial effect of the Mediterranean diet on disease activity and cardiovascular risk in SLE patients.
Article
Immunology
Haiping Xing, Haiyu Pang, Tian Du, Xufei Yang, Jing Zhang, Mengtao Li, Shuyang Zhang
Summary: In this study, atherosclerotic risk prediction model was built for SLE patients using RNA sequencing and differential expression analysis. The model, incorporating one gene and two clinical factors, demonstrated relatively high discrimination and calibration performance, providing valuable assistance for identifying atherosclerosis in SLE patients, especially asymptomatic ones.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Julia Mercader-Salvans, Maria Garcia-Gonzalez, Juan C. Quevedo-Abeledo, Adrian Quevedo-Rodriguez, Alejandro Romo-Cordero, Soledad Ojeda-Bruno, Fuensanta Gomez-Bernal, Raquel Lopez-Mejias, Candelaria Martin-Gonzalez, Miguel A. Gonzalez-Gay, Ivan Ferraz-Amaro
Summary: Ratios derived from complete blood count can be used as inflammatory biomarkers in systemic lupus erythematosus (SLE) patients. Despite lower cell counts, NLR, MLR, and PLR are higher in SLE patients. However, the relationship between these scores and disease characteristics is limited, with the complement system being the most consistent.
Article
Hematology
Leda Coelewij, Kirsty E. Waddington, George A. Robinson, Elvira Chocano, Thomas McDonnell, Filipa Farinha, Junjie Peng, Pierre Donnes, Edward Smith, Sara Croca, Jyoti Bakshi, Maura Griffin, Andrew Nicolaides, Anisur Rahman, Elizabeth C. Jury, Ines Pineda-Torra
Summary: This study found that patients with SLE have global changes in their lipoprotein profiles, but standard serum lipid measurements cannot accurately predict their risk of cardiovascular disease. Serum metabolites may be promising biomarkers to uncover the multi-metabolic phenotypes of subclinical atherosclerosis in SLE patients.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
(2021)
Letter
Rheumatology
Sindhu R. Johnson, Martin Aringer
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Health Care Sciences & Services
Jose Maria Pego-Reigosa, Carlos Pena-Gil, David Rodriguez-Lorenzo, Irene Altabas-Gonzalez, Nair Perez-Gomez, John Henry Guzman-Castro, Rodrigo Varela-Gestoso, Reyes Diaz-Lambarri, Alberto Gonzalez-Carrero-Lopez, Olga Miguez-Senra, Julia Boveda-Fontan, Angeles Charle-Crespo, Francisco Javier Carames-Casal, Ceferino Barbazan-Alvarez, Inigo Hernandez-Rodriguez, Francisco Maceiras-Pan, Marina Rodriguez-Lopez, Rafael Melero-Gonzalez, Jose Benito Rodriguez-Fernandez
Summary: An innovative program based on telemedicine was implemented to prioritize referrals from Primary Care to Rheumatology, resulting in reduced wait times and delays for face-to-face visits. The program achieved a resolution rate of 44.0%, with most patients being discharged after the first visit.
BMC HEALTH SERVICES RESEARCH
(2022)
Review
Pharmacology & Pharmacy
Nerea Garcia-Beloso, Irene Altabas-Gonzalez, Marisol Samartin-Ucha, Monica Gayoso-Rey, Maria Luisa De Castro-Parga, Angel Salgado-Barreira, Amelia Cibeira-Badia, Maria Guadalupe Pineiro-Corrales, Daniel Gonzalez-Vilas, Jose Maria Pego-Reigosa, Noemi Martinez-Lopez de Castro
Summary: From January 1, 2004 to June 30, 2021, a systematic review of studies on switching between reference adalimumab and biosimilars in different chronic immune-mediated inflammatory diseases found that the efficacy, safety, and immunogenicity were not affected by the switch. The findings were consistent across different adalimumab biosimilars and may be extended to other rheumatic diseases like psoriatic arthritis and ankylosing spondylitis.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2022)
Article
Rheumatology
Lucy M. Carter, Caroline Gordon, Chee-Seng Yee, Ian Bruce, David Isenberg, Sarah Skeoch, Edward M. Vital
Summary: The study aimed to develop a more accurate and time-efficient scoring tool for the BILAG-2004 index and validate its use. Easy-BILAG was developed, incorporating the items from the BILAG-BR dataset into a simplified single-page assessment. In the validation exercise, Easy-BILAG showed higher scoring accuracy and shorter completion time compared to the standard BILAG-2004. Clinicians rated Easy-BILAG as intuitive, convenient, and suitable for routine practice.
Article
Rheumatology
Maite Silva-Diaz, Francisco J. Blanco, Victor Quevedo Vila, Daniel Seoane-Mato, Fernando Perez-Ruiz, Antonio Juan-Mas, Jose M. Pego-Reigosa, Javier Narvaez, Neus Quilis, Raul Cortes, Antonio Romero Perez, Dolores Fabregas Canales, Teresa Font Gaya, Carolina Bordoy Ferrer, Francisco Javier Prado-Galbarro, Carlos Sanchez-Piedra, Federico Diaz-Gonzalez, Sagrario Bustabad-Reyes
Summary: This study estimated the prevalence of symptomatic axial osteoarthritis in Spain to be 19.17%, with higher rates in older individuals and those with higher body mass index. It was more common in women and in the central region of Spain, and less prevalent in those with higher education levels. Lumbar OA was more frequent than cervical OA and was associated with age and weight status.
RHEUMATOLOGY INTERNATIONAL
(2022)
Article
Rheumatology
Inigo Rua-Figueroa, David Rua-Figueroa, Natalia Perez-Veiga, Ana M. Anzola, Maria Galindo-Izquierdo, Jaime Calvo-Alen, Antonio Fernandez-Nebro, Clara Sanguesa, Raul Menor-Almagro, Eva Tomero, Natividad del Val, Esther Uriarte-Isazelaya, Ricardo Blanco, Jose L. Andreu, Alina Boteanu, Javier Narvaez, Tatiana Cobo, Cristina Bohorquez, Carlos Montilla, Esteban Salas, Francisco J. Toyos, Jose A. Bernal, Eva Salgado, Mercedes Freire, Antonio J. Mas, Lorena Exposito, Jose A. Hernandez-Beriain, Oihane Ibarguengoitia, Maria L. Velloso-Feijoo, Nuria Lozano-Rivas, Gemma Bonilla, Mireia Moreno, Inmaculada Jimenez, Victor Quevedo-Vila, Angela Pecondon, Elena Aurrecoechea, Elia Valls, Coral Mourino, Tomas Vazquez-Rodriguez, Jose M. Pego-Reigosa
Summary: Chronic heart failure is a common complication in patients with systemic lupus erythematosus (SLE), and treatment with antimalarials may have a cardioprotective effect.
SEMINARS IN ARTHRITIS AND RHEUMATISM
(2022)
Article
Cell Biology
Sara Martinez-Ramos, Carlos Rafael-Vidal, Jose M. Pego-Reigosa, Samuel Garcia
Summary: Spondyloarthritis is a family of chronic inflammatory diseases, with ankylosing spondylitis and psoriatic arthritis being the most prevalent. Monocytes and macrophages play key roles in the pathogenesis of these diseases.
Article
Rheumatology
Goncalo Durao-Carvalho, Raquel Fernandez-Gonzalez, Bethan Goulden, Filipa Farinha, David Isenberg
Summary: The study found that patients with white ethnicity, older age at diagnosis, absence of renal involvement, and no antiphospholipid syndrome (APS) were more likely to achieve sustained complete remission (CR) in systemic lupus erythematosus (SLE). Patients who did not achieve any kind of sustained remission had a higher risk of early mortality.
Article
Rheumatology
Weike Luo, Filipa Farinha, David A. Isenberg, Anisur Rahman
Summary: In this study, non-Caucasian ethnicity and younger age at diagnosis are associated with the risk of developing LN in SLE patients. There is evidence of improvement in survival among SLE patients over time.
Article
Rheumatology
Chee-Seng Yee, Caroline Gordon, Mohammed Akil, Peter Lanyon, Christopher J. Edwards, David A. Isenberg, Anisur Rahman, Lee-Suan Teh, Sofia Tosounidou, Robert Stevens, Athiveeraramapandian Prabu, Bridget Griffiths, Neil McHugh, Ian N. Bruce, Yasmeen Ahmad, Munther A. Khamashta, Vernon T. Farewell
Summary: The study found that the BILAG-2004 index is associated with the development of new damage in SLE patients. Low disease activity states can be considered as treatment targets.
Review
Rheumatology
Ana Lorenzo-Vizcaya, David Alan Isenberg
Summary: Systemic lupus erythematosus (SLE) is an autoimmune rheumatic disease characterized by the production of auto-antibodies and inflammatory response. Effective therapies for SLE are needed, as some drugs have shown success in phase II trials but failed in phase III trials. This review focuses on specific drugs and explores the reasons for their failure or success.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Nicola Farina, Ruya Abdulsalam, Thomas McDonnell, Charis Pericleous, Amrita D'Souza, Vera M. Ripoll, Jemma Webster, David A. Isenberg, Ian Giles, Anisur Rahman
Summary: Double/triple-positivity for IgG anti-CL, anti-beta 2GPI and anti-DI in early SLE identifies a population at higher risk of subsequent VE.
Editorial Material
Rheumatology
Joana Rua, Maria Dall'Era, David Isenberg
Editorial Material
Rheumatology
David A. Isenberg, Celia J. F. Lin
Article
Rheumatology
Chris Wincup, Nicky Dunn, Caroline Ruetsch-Chelli, Ali Manouchehrinia, Nastya Kharlamova, Meena Naja, Barbara Seitz-Polski, David A. Isenberg, Anna Fogdell-Hahn, Coziana Ciurtin, Elizabeth C. Jury
Summary: The study found that high levels of anti-drug antibodies (ADA) to rituximab were persistent in patients with SLE undergoing treatment. ADA accelerated the elimination of the drug and were associated with an increased rate of relapse. In addition, in vitro experiments confirmed the neutralizing capacity of ADA to rituximab.